Rebiotix to Present at Piper Jaffray 28th Annual Healthcare Conference


Download this press release (153 KB).

ROSEVILLE, MN (November 16, 2016) — Rebiotix Inc., a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that it will present at Piper Jaffray 28th Annual Healthcare Conference, to be held November 29-30, 2016, at the Lotte New York Palace Hotel in New York City.

Lee Jones, co-founder, president and CEO, will present Rebiotix’s corporate growth strategy and its position as the most clinically advanced microbiome company in the industry. Topics in the presentation will include a review of Rebiotix’s pioneering Microbiota Restoration Therapy (MRT) platform and its drug development pipeline, which is led by RBX2660, the company’s Phase 3-ready drug candidate for the prevention of recurrent Clostridium difficile infection.

Event: Piper Jaffray 28th Annual Healthcare Conference
Date: Wednesday, November 30, 2016
Time: 8:30 a.m. (Eastern Time)
Location: Lotte New York Palace Hotel – Track 6, Kennedy 1, 4th Floor


About Rebiotix Inc.

Rebiotix Inc. is a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its Phase 3-ready drug candidate, RBX2660, having recently completed a Phase 2b randomized, double-blind, placebo-controlled trial as a possible prevention of recurrent Clostridium difficile (C. diff.) infection after a standard of care course of antibiotics (PUNCH™ CD2). RBX2660 has been granted Orphan Drug status, Fast Track status and Breakthrough Therapy Designation from the FDA for its potential to prevent recurrent C. diff. infection. Rebiotix’s development pipeline includes multiple formulations targeting several disease indications and is built around its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

Rebiotix Media Contact:

Amy Wheeler
Tiberend Strategic Advisors
646-­362-­5750
awheeler@nulltiberend.com